Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market open
8 174,18 pts
+0.34%


Last updated : 19/11/2026 - 12h30
🏠 Home   ➤    Stock news

Inventiva shares lead the SBF 120 gainers despite a 14% weekly drop

The Burgundy-based biotech specialising in fibrotic and metabolic diseases rebounds at midday, in a Paris market that is edging higher. The rise places it near the top of the index table, a few days after a sharp decline.


Inventiva shares lead the SBF 120 gainers despite a 14% weekly drop

A rebound that recovers only part of the weekly losses

Inventiva shares gain 3.44% to €3.01 during the session, while the SBF 120 rises 0.34% and ranks among the index's strongest performers.

The move softens, without erasing, the 14.12% loss recorded over seven days, and leaves the stock well below its level of three months ago (-23.12%). Over one month, it still shows a gain of 10.05%, achieved during the rebound in October and early November.

Technically, the price remains below its three moving averages: the gap is 8.51% with the MM20 (€3.29) and 3.53% with the MM50 (€3.12), which the stock had regained in early November before losing it again. The support at €2.65 and the resistance at €3.59 frame the current trading range.

Cash runway until end-2027 and revenue expected on November 23

When it published its H1 2026 results on July 29, the company indicated that its cash did not cover operating requirements for the next twelve months, and set its financing horizon at the end of the second quarter of 2027 without additional funding. It recorded no revenue in the first half, compared with €4.5 million a year earlier.

Among the levers cited were the €103 million capital offering and the €75 million financing transaction announced on June 2, as well as the possible exercise of warrants that could bring in up to €116 million.

Inventiva is listed in Paris and on the Nasdaq in the form of ADSs, one security across two markets; the Paris line dominates trading. The next scheduled event is the publication of third-quarter 2026 revenue on November 23.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: S1 2026
Key reported figures
  • Revenue: 0 millions d'euros
  • Quarterly revenue: 0 millions d'euros
  • Revenue growth: -100 %
  • Net income: -69,5 millions d'euros
  • Free cash flow: -48,7 millions d'euros
Risks mentioned
  • La trésorerie actuelle ne couvre pas les besoins opérationnels des 12 prochains mois.
  • Horizon de trésorerie limité à la fin du deuxième trimestre 2027 sans financements additionnels.
  • Aucun chiffre d'affaires enregistré au premier semestre 2026, contre 4,5 M€ un an plus tôt.
Opportunities identified
  • Offre Equity de 103 M€ et Opération de Financement de 75 M€ annoncées le 2 juin 2026.
  • Tranche C de l'Opération de Financement pouvant apporter jusqu'à 20,0 M€.
  • Exercice des warrants Tranche 3 pouvant générer jusqu'à 116,0 M€.

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours